Novo Nordisk, Anthropic Team Up For AI Drug Research
Novo Nordisk taps Anthropic AI to speed medicine research, enhance software workflows, and implement responsible data governance standards.
Stocks · News reference
Why Is Tempus AI Stock Gaining Thursday?
Tempus AI (TEM) trades higher after positive Phase 3 mRNA cancer trial results spotlight its $1.5B acquisition of Personalis.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Is Cancer the Turnaround Moderna Has Been Looking for Post-COVID?
Moderna reported positive Phase III results for its personalized mRNA cancer therapy (intismeran autogene) developed with Merck, showing significant improvements in recurrence-free and distant metastasis-free survival in melanoma patients. The breakthrough validates Moderna's mRNA platform beyond vaccines and opens opportunities across multiple tumor types, while the company simultaneously expands its respiratory vaccine portfolio with RSV, flu, and combination vaccines to reduce COVID-19 dependence.
Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study
Immunocore announced it has enrolled 540 patients in the phase III TEBE-AM study evaluating Kimmtrak as monotherapy and in combination with Merck's Keytruda versus investigator's choice in previously treated advanced melanoma. The company expects top-line overall survival data as early as end of 2026. Kimmtrak sales grew 16% year-over-year to $222.6 million in the first half of 2026.
Immunotherapy Drugs Market 2026: Precision Medicine, Next-Generation Biologics and Expanding Cancer Indications Fuel Growth Opportunities
The global immunotherapy drugs market is experiencing significant growth driven by advances in biotechnology, rising demand for targeted treatments, and expanding therapeutic applications across cancer, autoimmune, and inflammatory diseases. Key growth factors include increasing disease burden, robust drug pipelines, personalized medicine adoption, and combination therapy development. The Americas and Europe remain dominant markets, while Asia-Pacific is emerging as a high-growth region. Major pharmaceutical and biotech companies are increasing R&D investments and collaboration to accelerate innovation.
Moderna (MRNA) Ascends While Market Falls: Some Facts to Note
Moderna (MRNA) closed at $146.69, up 1.89%, outperforming the S&P 500 despite rising 127.37% in the past month. However, the company faces headwinds with expected EPS of -$1.36 (down 166.67% YoY) and revenue projected at $888.78 million (down 12.52% YoY). The stock holds a Zacks Rank #3 (Hold) rating with a modest 1.42% increase in consensus EPS estimates over 30 days.
Why Is Techne (TECH) Down 0.1% Since Last Earnings Report?
Bio-Techne (TECH) reported Q4 adjusted EPS of 52 cents, meeting consensus estimates but declining 1.9% year-over-year. Full-year adjusted EPS of $1.93 increased 0.5% and surpassed consensus by 1%. Q4 revenues of $321.2 million exceeded estimates by 1.26%, though organic growth was modest at 3%. The company improved its balance sheet with cash increasing to $264.7 million and debt declining to $200 million. However, analysts have issued no estimate revisions in the past two months, and the stock carries a Zacks Rank #3 (Hold) with weak growth and momentum scores.